 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
|
|
| |
| Company Profile |
| |
|
Axonyx, Inc., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical compounds for the treatment of Alzheimer's disease (AD) and central nervous system neurodegenerative diseases. It primarily develops Phenserine, a symptomatic and disease progression treatment of mild to moderate AD; Posiphen, a disease progression treatment for AD; and BisNorCymserine, a symptomatic treatment of severe AD. The company, through its subsidiary, OXIS International, Inc., also involves in the development of research diagnostics, nutraceuticals, and therapeutics in the field of oxidative stress. It has a license agreement with Applied Research Systems ARS Holding N.V., covering the amyloid and prion inhibitory peptide technologies. Axonyx was incorporated in 1997 and is headquartered in New York City.
|
|
|
|
|
